Haohai Acquires China Rights to Eirion Dermatology Products in $527 Million Deal

Shanghai Haohai Biological announced a $527 million agreement to develop Eirion Therapeutics' aesthetic dermatology products in China .. Haohai will pay $8 million upfront and make a $32 million investment in Eirion Series A Preferred Stock. It will also provide up to $43 million in development funds and be responsible for paying up to $444 million in sales milestones. Haohai is a well-established company that markets a large variety of products in China and global markets. Eirion is located in Woburn , MA . More details.... Stock Symbols: (HK: 6826; SHA: 688366) Share this with colleagues: // //